2408.HK

Chinese noodle-chain operator Guangzhou Xiao Noodles Catering Co. Ltd. (2408.HK) launched its Hong Kong public offering on Thursday, aiming to raise up to HK$690 million ($89 million) by selling 97.3 million shares for between HK$5.64 and HK$7.04. The stock is set to make its trading debut on Friday next week.

Founded in 2014, Xiao Noodles specializes in Sichuan-Chongqing noodle cuisine and operates a chain of 451 restaurants across 22 Mainland Chinese cities, with an additional 14 outlets in Hong Kong, and 115 more stores under development. The company’s revenue rose 34% year-on-year in the first half of this year to 703 million yuan, while its net profit surged 96% to 41.83 million yuan.

According to its latest prospectus, Xiao Noodles has secured HHLRA, Guotai Junan Securities, Junyi Hong Kong Fund, Shengying Investment, Zeta Fund and Haidilao Singapore – a wholly owned subsidiary of hotpot chain Haidilao – as cornerstone investors for the listing, with total commitments of about $22 million.

Xiao Noodles said it will use the IPO proceeds to expand its restaurant network, upgrade its restaurant technology and digital systems, enhance brand building, invest in potential upstream food-processing projects and support its general corporate operations.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…